Tag: pharmaceuticals
-
Nicotine Destroying Drug Candidate Discovered
7 August 2015. Biochemists at Scripps Research Institute reported on an enzyme derived from naturally-occurring bacteria that shows in lab tests can remove nicotine in the blood, with potential as a drug to help smokers quit. The team from the lab of chemistry professor Kim Janda at Scripps’s La Jolla, California campus described their findings…
-
Peanut Allergy Therapy Company Raises $160 Million in IPO
6 August 2015. Aimmune Therapeutics Inc., a developer of treatments for peanut and other food allergies, raised $160 million from its initial public stock offering, pricing its 10 million shares at $16.00. Shares in the Brisbane, California company trade on the Nasdaq exchange under the symbol AIMT. Shares closed today (6 August), priced at $24.10…
-
Pharma Licenses University Antibiotic Enhancements
5 August 2015. Technologies that remove side-effect causing toxicity from gentamicin, a powerful antibiotic drug, are being licensed from two universities by La Jolla Pharmaceutical Company. Financial terms of the agreements between the San Diego biopharmaceutical developer and University of Alabama in Birmingham and University of Indiana were not disclosed. Gentamicin is one of a…
-
Gates Expands Collaboration with RNA Vaccine Maker
4 August 2015. CureVac, a designer of vaccines and therapies based on messenger RNA — genetic signals sent from DNA to a person’s cells — is expanding its partnership with the Bill and Melinda Gates Foundation to include a third viral disease affecting low-resource regions. Financial details of the new collaboration between the Gates Foundation…
-
Robotics Harnessed to Produce Adult Stem Cells
4 August 2015. An automated system now uses robotics instead of manual lab handling to convert skin samples from individuals into stem cells that can transform into any other cells in the body, for regenerative medicine, drug development, and research. The system, developed at New York Stem Cell Foundation, or NYSCF, is described in yesterday’s…
-
Trial Shows Weekly Growth Hormone Drug Effective, Safe
30 July 2015. Results of an intermediate-stage clinical trial show a drug candidate to treat growth hormone deficiency in children given once a week, works about as well as a current therapy requiring a daily injection. The results were released by Ascendis Pharma A/S, a specialty pharmaceutical company in Copenhagen, Denmark that conducted the trial.…
-
Opioid Overdose Nasal Spray Cleared for FDA Review
29 July 2015. Indivior plc, a pharmaceutical company in the U.K. specializing in addiction therapies, received notice that the U.S. Food and Drug Administration accepted the company’s new drug application and is beginning review of Indivior’s opioid overdose treatment formulated as a nasal spray. The FDA also granted Indivior, in Slough, U.K., priority review status…
-
FDA Clears Trial of Fibrosis Drug for Muscular Dystrophy
24 July 2015. Biotechnology company Fibrogen Inc. says the U.S. Food and Drug Administration approved an application to test its fibrosis drug candidate in patients with Duchenne muscular dystrophy. The company says FDA’s approval was part of a new drug application for its candidate, code-named FG-3019, already in intermediate-stage clinical trials as a therapy for…
-
Allergan Acquires Depression Therapy Developer for $560M
27 July 2015. Pharmaceutical maker Allergan plc is acquiring Naurex Inc., a designer of fast-acting therapies for depression and other neurological disorders, for $560 million. The deal covers Naurex’s products now in clinical trials, with the company’s technology platform and preclinical research spun-off into a new enterprise. Naurex, a spin-off company from Northwestern University in…
-
Research, Finance Alliance to Fast-Track Alzheimer’s Drugs
24 July 2015. A coalition of research institute, venture capital firm, and drug discovery company is forming a new enterprise to develop therapy candidates for Alzheimer’s disease from promising lab results. Financial terms of the partnership of Gladstone Institutes and Dolby Family Ventures in San Francisco with Evotec AG in Hamburg, Germany were not disclosed.…